Background
Age-related GH decline (somatopause) contributes substantially to the body composition changes of aging: progressive loss of muscle mass (sarcopenia), accumulation of visceral and subcutaneous fat, and reduced bone mineral density. GH secretagogues — including synthetic peptides such as GHRP-2, GHRP-6, and the highly selective ipamorelin — stimulate endogenous GH pulsatility through the ghrelin receptor (GHSR-1a) and represent a targeted approach to partially reversing somatopause without exogenous GH.
Jette and colleagues evaluated GHRP administration in a cohort of healthy elderly adults to determine whether secretagogue-driven GH restoration translates into clinically meaningful body composition improvement in the aging population.
Key Findings
GH Axis Restoration:
- Peak GH response to GHRP challenge increased 3.2-fold vs. placebo at 3-month follow-up
- 24-hour integrated GH area under the curve increased approximately 2.8-fold
- IGF-1 rose from a mean of 98 ng/mL (low-normal for age) to 136 ng/mL (+38%), approaching younger adult reference ranges
- GH pulsatility preserved — the secretagogue amplified endogenous pulses rather than creating supraphysiological tonic GH levels
Body Composition Changes:
| Parameter | GHRP Group | Placebo Group | Difference |
|---|---|---|---|
| Fat-free mass change (kg) | +1.4 | −0.2 | +1.6 kg (p < 0.05) |
| Fat mass change (kg) | −2.1 | +0.3 | −2.4 kg (p < 0.05) |
| Waist circumference (cm) | −3.2 | +0.8 | −4.0 cm (p < 0.05) |
| Grip strength (kg) | +2.8 | +0.4 | +2.4 kg (p < 0.05) |
- Meaningful lean mass gains in elderly subjects with pre-existing age-related sarcopenia
- Visceral fat reduction reflected by waist circumference improvement
- Functional strength improvement (grip strength) consistent with lean mass accretion
Tolerability:
- No serious adverse events in the elderly cohort
- Transient water retention in the first 2 weeks (consistent with GH axis activation); resolved without dose adjustment
- Fasting glucose unchanged; no significant insulin sensitivity deterioration
- No cortisol or ACTH elevation — consistent with class-selective GHRP compounds
Mechanism
GHRP peptides act at GHSR-1a receptors in the hypothalamus and anterior pituitary to amplify GHRH-mediated GH release. In elderly adults, the GHSR-1a responsiveness is preserved even as endogenous GHRH secretion declines — making secretagogue stimulation particularly effective for restoring age-related GH deficiency without supraphysiological GH spikes.
Ipamorelin is the most selective member of this peptide class, sharing the same GHSR-1a mechanism but with a cleaner selectivity profile (no prolactin, ACTH, or cortisol stimulation), making the body composition findings from GHRP class studies directly applicable.
Clinical Significance
- Sarcopenia intervention: The 1.4 kg lean mass gain with functional strength improvement suggests GH secretagogue peptides are mechanistically appropriate for age-related muscle loss
- Visceral fat reduction: Elderly patients with metabolic syndrome benefit from both the anabolic and lipolytic components of restored GH secretion
- Tolerability in elderly: No glucose impairment or serious adverse events despite physiologically meaningful IGF-1 elevation — favorable safety profile for the aging population
- Functional endpoints: Grip strength improvement confirms that lean mass changes translate to meaningful functional outcomes, not just DEXA changes
Limitations
- Short 3-month duration; sarcopenic reversal likely requires sustained therapy beyond this window
- Elderly population only; results may not apply to younger adults seeking body composition optimization
- GHRP used in this study may differ in selectivity profile from ipamorelin (newer, more selective agent)
- No dietary standardization across the study; nutritional differences could affect body composition outcomes
- No control for physical activity levels, which modulates GH secretagogue response magnitude